Uromigos-ESMO

Advertisement
The UromigosThe Uromigos | November 20, 2024
Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024.
Listen Now
The UromigosThe Uromigos | September 23, 2024
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
The UromigosThe Uromigos | September 19, 2024
Fresh off the Presidential session address, Tom discusses his data with Petros commenting.
The UromigosThe Uromigos | September 16, 2024
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
The UromigosThe Uromigos | September 17, 2024
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC.
The UromigosThe Uromigos | September 17, 2024
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotin + pembrolizumab in bladder cancer.
The UromigosThe Uromigos | September 17, 2024
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024.
The UromigosThe Uromigos | November 21, 2024
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC.
The UromigosThe Uromigos | September 23, 2024
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC.
The UromigosThe Uromigos | September 23, 2024
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
The UromigosThe Uromigos | September 11, 2024
Dr. Gillessen joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024.
The UromigosThe Uromigos | October 31, 2023
Silke Gillessen, MD, PhD recaps some of the kidney, bladder, and prostate cancer data from this year's ESMO meeting.
The UromigosThe Uromigos | October 31, 2023
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
The UromigosThe Uromigos | November 13, 2023
Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC.
The UromigosThe Uromigos | October 30, 2023
Michiel Van der Heijdan, MD, PhD, discusses EV-302 and CheckMate-901 on EV plus pembrolizumab and nivolumab plus ipilimumab.
The UromigosThe Uromigos | October 30, 2023
Yohann Loriot, MD, PhD, gives an update on the use of erdafitinib within the THOR randomized phase 3 trial.
The UromigosThe Uromigos | October 30, 2023
Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023.
The UromigosThe Uromigos | October 30, 2023
Dr. Brad McGregor discusses the DAD trial on sacituzumab govitecan plus enfortumab vedotin for the treatment of mUC.
The UromigosThe Uromigos | October 30, 2023
Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC.
The UromigosThe Uromigos | October 13, 2023
Silke Gillessen, MD, PhD joins us to discuss the upcoming ESMO conference and panels of interest to look out for.
Advertisement
Advertisement
Advertisement